OOIR: Observatory of International Research

Papers

(The TQCC of JAMA Neurology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Error in Figure and Table	410
CC-BY Open Access Added	355
Error in Figure Legends	314
JAMA Neurology	312
Risk of Hemorrhagic Stroke in Patients With Coronavirus Disease 2019	250
Photon-Counting Computed Tomography Scan of a Cerebrospinal Fluid Venous Fistula	245
Location and Timing of Recurrent, Nontraumatic Intracerebral Hemorrhage	244
Acute Ischemic Stroke Care Quality Improvement	236
Autoimmune Inflammatory Astrocytopathies—Is the Spectrum Expanding?	221
Equipping AI for Unbiased and Inclusive Neurology	211
Ischemic Stroke Due to Compression of a Wandering Internal Carotid Artery by the Hyoid Bone	201
Errors in the Title, Short Title, and Additional Contributions	198
Adequate Initial Dosage and Tapering Methods of Steroids to Reduce the Total Corticosteroid Dose in Myasthenia Gravis	198
Ghrelin for Neuroprotection in Post–Cardiac Arrest Coma	197
Prevalence, Timing, and Network Localization of Emergent Visual Creativity in Frontotemporal Dementia	171
Error in Table	171
Craniocervical Junction Calcium Pyrophosphate Deposition Causing Hypoglossal Nerve Palsy	169
Error in Title	166
Error in Open Access Status	166
Error in Open Access Status	166
Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults	162
Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles	161
JAMA Neurology	157
Stay for the Eulogy	156
An Acetylcholine M₁ Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment	155

Errors in the Author Affiliations and Figure 1 Legend	152
JAMA Neurology	149
JAMA Neurology	147
Facial Numbness, Dysarthria, Muscle Atrophy, and Weakness in a Young Patient	146
JAMA Neurology Peer Reviewers in 2020	145
Rare APOE Missense Variants—Can We Overcome APOE ε4 and Alzheimer Disease Risk?	141
Isolated Myoclonus of the Vocal Folds in Alexander Disease	137
MOG-IgA as a Potential Marker of Germinal Center Activity	137
Comments on the Evaluation of Suicidality Risk of Newer Antiseizure Medications—Reply	134
Disentangling Workflow Paradigms and Treatment Decision-Making in Acute Ischemic Stroke—Reply	126
Practical Advice on Surviving and Thriving as an Academic Physician-Neuroscientist	125
Cerebral Amyloid Angiopathy and Risk of Isolated Nontraumatic Subdural Hemorrhage	124
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes	124
Errors in Table 1 and Figure 2	123
Recurrent Ischemic Stroke in Patients With Atrial Fibrillation While Receiving Oral Anticoagulants	122
When Pregnancy Becomes an Inclusion Criterion in Neuroscience Research	121
Multimodal Neuroimaging of Intimal Flap in a Basilar Artery Dissection	119
Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination	114
Sequential Bilateral Vision Loss in a Woman With Scalp Tenderness and Jaw Claudication	110
I Only Want to See You—A Challenge of Long-term Clinician-Patient Relationships in Team-Based Clinical Care	109
Visualizing Hyperhidrosis With Water-Erasable Ink	108
Traumatic Brain Injury Recovery Trajectories in Patients With Disorders of Consciousness	108
Magnetic Resonance Imaging Features of Encephalitis of Scrub Typhus	107
JAMA Neurology	106
APOE Genotype and White Matter Hyperintensities in Sporadic Alzheimer Disease—Reply	104
Abandoning the Proteinopathy Paradigm in Parkinson Disease	103
Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention	103
Error in Figure	102
Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis	100
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value	99
Challenges and Opportunities for Clinical Trials in Patients With Glioma	95
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy	95
Bilateral Complete Ophthalmoplegia in a 50-Year-Old Man	91
New Approaches to Challenge Old Assumptions—B-Cell Depletion in Multiple Sclerosis	89
Cerebral Ultrasonography of Cytotoxic Edema in a Newborn With a Mitochondrial Disorder	88
Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration	88
A 31-Year-Old Man With Bilaterally Limited Mobility of Joints	88
Flapping Scalp Sign as a Rare and Interesting Presentation in Delayed Postoperative Tension Pneumocephalus	86
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal	85
Cortical Hemiballismus Associated With an Insular and Temporal Lobe Infarct	84
Diplopia and Ptosis in an Older Woman	83
The Shrinking Roles of Clinical Research and Education for Academic Neurologists	81
Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities—Reply	79
Error in Figure 2	79
Posterior Reversible Encephalopathy Syndrome in a Child With Renovascular Hypertension	78
JAMA Neurology	77
Myocardial Infarction Bends the Curve of Age-Related Cognitive Decline, but How?	77
Discussion on the Application of Rapid Immunoblot Assay for AQP4-IgG Detection	76
Error in Author Name, Figure 3A and C, and Table 1	76
Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion	75

Frequency and Underlying Pathology of Pure Vascular Cognitive Impairment	75
Optimizing the Time Course of Risks and Benefits of Acute Dual Antiplatelet Therapy for Stroke Prevention	73
Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination	73
US Food and Drug Administration Approval of Aducanumab—Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?	72
Advocating for Demonstration of Disease Modification—Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?	72
JAMA Neurology	71
Association of Tourette Syndrome and Chronic Tic Disorder With Cervical Spine Disorders and Related Neurological Complications	71
Substantia(l) Impacts of Contact Sport Play and Parkinsonism	70
Bilateral Focused Ultrasound Thalamotomy for Tremor—Is It Really Safe?	68
Fecal Microbiota Transplantation for Treatment of Parkinson Disease	67
Substantia Nigra Pathology, Contact Sports Play, and Parkinsonism in Chronic Traumatic Encephalopathy	66
Itching Frequency and Neuroanatomic Correlates in Frontotemporal Lobar Degeneration	64
Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities	63
Temporal Dynamics and Biological Variability of Alzheimer Biomarkers	63
Wildfire Smoke Exposure and Incident Dementia	63
Transient Focal Neurological Events in Cerebral Amyloid Angiopathy and the Long-term Risk of Intracerebral Hemorrhage and Death	62
Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance	62
Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era	62
Women in Stroke Trials—A Tale of Perpetual Inequity in Cardiovascular Research	61
Time Windows Between Symptom Onset and Treatment—An Outdated Myth	61
Type 1 Myocardial Infarction in Patients With Acute Ischemic Stroke	61
Time to Think About Myocardial Infarction in Acute Ischemic Stroke	61
Neurologic Alternative Payment Models—Bridging the Gap	60
Origin of Transthyretin in Cerebral Amyloid Angiopathy	58
Psychedelics in Addiction Treatment—Navigating a Sociopolitical Rift	58
Targeting Sleep and Circadian Function in the Prevention of Alzheimer Disease	57
Early Posttraumatic Seizures—Putting Things in Perspective	57
Error in Figures 2 and 3	57
Assessing Brain Capillaries in Coronavirus Disease 2019	56
Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis	56
Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment	55
Automated Imaging Differentiation for Parkinsonism	55
Unconvincing Evidence of SARS-CoV-2–Associated Myositis in Autopsied Muscles	55
Error in Author Name	54
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis	54
Venture Capital Investment in Neurology Companies	54
Angiotensin Receptor Blockers for Hypertension and Risk of Epilepsy	53
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation	53
Heatwaves and Neurodegenerative Disease	53
Risk of Perinatal and Maternal Morbidity and Mortality Among Pregnant Women With Epilepsy	53
Neurologic Complications of Smallpox and Monkeypox	53
Antiseizure Medication Concentrations During Pregnancy	53
Effect of Tranexamic Acid Administration on Remote Cerebral Ischemic Lesions in Acute Spontaneous Intracerebral Hemorrhage	53
The Current Status of Next-Generation Sequencing for Diagnosis of Central Nervous System Infections	52
Change in Epidemiology of Creutzfeldt-Jakob Disease in the US, 2007-2020	52
On Cave Paintings and Shallow Waters—The Case for Advancing Spinal Cord Imaging in Multiple Sclerosis	52
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy	51
Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy	51
Perils of Race-Based Norms in Cognitive Testing	50
Risks of Expanded Medicare Coverage of Carotid Artery Stenting	50
Neurocysticercosis as an Eradicable Cause of Epilepsy	50
Brain Networks for Cortical Atrophy and Responsive Neurostimulation in Temporal Lobe Epilepsy	50
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations	50
JAMA Neurology	50
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin	49
Batoclimab vs Placebo for Generalized Myasthenia Gravis	49
Why Some Individuals With Tourette Syndrome Experience Assault and Perpetrate Criminal Behavior	49
Early Seizure Prophylaxis in Mild and Moderate Traumatic Brain Injury	48
Home Health Management of Parkinson Disease Deep Brain Stimulation	48
Assessment of Optimal Patient Selection for Endovascular Thrombectomy Beyond 6 Hours After Symptom Onset	48
Mobile Stroke Units—Time for Legislation and Remuneration	48
Risk of Stroke, Death, and Myocardial Infarction Following Transcarotid Artery Revascularization vs Carotid Endarterectomy in Patients With Standard Surgical Risk	48
Predictors of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease	47
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases	47
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine	47
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers	47
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy	47
Prehospital Comprehensive Stroke Center vs Primary Stroke Center Triage in Patients With Suspected Large Vessel Occlusion Stroke	46
Physical Frailty, Genetic Predisposition, and Incident Parkinson Disease	46
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study	46
Electronic Cigarette Use and Cigarette-Smoking Cessation Attempts Among Stroke Survivors in the US	46
Association of Field Position and Career Length With Risk of Neurodegenerative Disease in Male Former Professional Soccer Players	46
Association of Dementia Risk With Focal Epilepsy and Modifiable Cardiovascular Risk Factors	46
An Opportune Time for Newborn Screening in Duchenne Muscular Dystrophy	45
Association Between Increased Seizures During Rewarming After Hypothermia for Neonatal Hypoxic Ischemic Encephalopathy and Abnormal Neurodevelopmental Outcomes at 2-Year Follow-up	44
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis	44
Immediate- or Delayed-Intensive Statin in Acute Cerebral Ischemia	44
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis	44
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack	43
Reperfusion Treatment and Stroke Outcomes in Hospitals With Telestroke Capacity	43

Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain	42
White Matter Tract Density Index Prediction Model of Overall Survival in Glioblastoma	42
Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis	42
Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy	41
Association of APOE Genotypes and Chronic Traumatic Encephalopathy	41
Optimal Intensity and Duration of Walking Rehabilitation in Patients With Chronic Stroke	41
Comorbidity and Disease Activity in Multiple Sclerosis	41
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation	40
Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia	39
Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy	39
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels	38
Toward More Personalized Management of Device-Detected Atrial Fibrillation	38
Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia	37
Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort Study	37
Diagnosing Preclinical and Prodromal Neurodegenerative Diseases—The Clinical Is Political	37
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes	37
Plasma Biomarkers of Tau and Neurodegeneration During Major Cardiac and Noncardiac Surgery	37
A Call to Action to Address Sex Differences in Alzheimer Disease Clinical Trials	37
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease	37
Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases	37
Association Between Treatment Progression, Disease Refractoriness, and Burden of Illness Among Hospitalized Patients With Status Epilepticus	36
Lecanemab and APOE Genotyping in Clinical Practice—Navigating Uncharted Terrain	36
Trends in Mortality Rates Among Medicare Enrollees With Alzheimer Disease and Related Dementias Before and During the Early Phase of the COVID-19 Pandemic	36
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis	36
Occult Breast Cancer With Anti-Ri Antibody Positivity and Pontine Hot Cross Bun Sign	36
Risk Factors for Young-Onset Dementia in the UK Biobank	35
Head Injury and Long-term Mortality Risk in Community-Dwelling Adults	34
Trends in Suicide Rates Among Post-9/11 US Military Veterans With and Without Traumatic Brain Injury From 2006-2020	34
Incorrect Nomenclature May Lead to Questionable Concepts	34
Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease	33
One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability	33
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease	33
Risk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US	33
Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity	32
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease	32
Association of Short and Long Sleep Duration With Amyloid-β Burden and Cognition in Aging	32
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease	32
Diverging Temporal Trends in Stroke Incidence in Younger vs Older People	32
Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia	32
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment	32
Seizure Cycles in Focal Epilepsy	31
Error in Author Surname	31
JAMA Neurology	31
Neuromodulation for Children With Hemiparesis and Perinatal Stroke	31
Error in Open Access Status	31
Neuro-Advocacy—Professionalism in Action	30
JAMA Neurology	30
Neurogenic Unilateral Leg Edema	30
Dynamic Tremor in a Patient With Parkinson Disease	29
Public Access to Scientific Research Findings and Principles of Biomedical Research—A New Policy for the JAMA Network	28
Alternate Hemibody Hyperkinetic and Hypokinetic Movement Disorders Due to Strategic Lesions in Cerebral Toxoplasmosis	28
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition	28
JAMA Neurology—The Year in Review, 2020	28
Changing Health Care Markets Have the Potential to Undermine Stroke Systems of Care	28
JAMA Neurology	28
Progressive Camptocormia With Head Drop and Dysphagia	28
Error in Methods	28
A Butterfly Flaps Its Wings	27
Ondine’s Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity	27
Inducers and Cardiovascular Risk—Potential Role for Lowered Drug Exposure	27
The Other Dementia Breakthrough—Comprehensive Dementia Care	27
Light Reading—The Gravity of Postoperative Care	27
Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era—Reply	27
Severe Cervicodynia in a Patient With Pustules on the Palms	27
JAMA Neurology Peer Reviewers in 2022	26
Bilateral Vagus Nerve Enhancement in a Patient With Leptomeningeal Lymphoplasmacytic Lymphoma Presenting with Intractable Hiccups	26
Circadian Motor Improvement in MS and Core Body Temperature Dipping	26
Error in Figure 2	26
Protecting Neural Data Privacy—First, Do No Harm	26
JAMA Neurology	26
A Unique Case of Opioid-Induced Myoclonus	26
Is It Really Itching?	26
Hello, My Name is Doctor	25
JAMA Neurology—The Year in Review, 2022	25
A Clown With Traumatic Brain Injury	25
Abandoning the Proteinopathy Paradigm in Parkinson Disease—Not So Fast—Reply	24
Paging Global Neurology Organizations—The Time Is Now for More Inclusive Leadership	24
JAMA Neurology	23
Timing of Physical Therapy Sessions for Individuals With Parkinson Disease May Unlock Benefits	23
Error in Abstract	23
Respiratory Care for Patients With Amyotrophic Lateral Sclerosis in the US	23
I Do Care	23
Risk of Hemorrhagic Stroke in Patients With Coronavirus Disease 2019—Reply	23
The Promise and Peril of the Patient Portal	23
Title Updated	23
Error in Figure Captions	23
Error in Figure	22
Identification and Treatment of Neonatal Seizures During Therapeutic Hypothermia and Rewarming—Reply	22
Changes in the Rate of Leucine-Rich Glioma-Inactivated 1 Seropositivity During the COVID-19 Lockdown	22
Teleneurorehabilitation and Motor and Nonmotor Symptoms and Quality of Life in Parkinson Disease	22
Magnetic Resonance Imaging Features of Tropical Candidal Meningoencephalitis	22
Evolving Perspectives on α-Synuclein Testing	22
A Funeral for a Neurologist	21
E-Cigarettes and Stroke Risk—Present Uncertainties and Future Directions	21
Advancing the Neuropalliative Care Approach—A Call to Action	21